Mesa Laboratories, Inc. Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2019. The request metadata identifies “2017 Q4,” but the supplied filing is the fiscal 2019 annual report, filed June 3, 2019.
Business Context
Mesa designs, manufactures, and markets quality-control products and services used in regulated niche markets. Its four divisions are Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. Approximately 37% of fiscal 2019 sales came from customers outside the United States. The company had 347 employees as of March 31, 2019.
Products include sterilization and cleaning indicators, medical and industrial instruments, wireless environmental monitoring systems, related software and services, and thermal packaging products.
Financial Performance and Liquidity
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $103.1 million | $96.2 million | Up 7% |
| Gross profit | $60.9 million | $54.6 million | Up 12% |
| Gross margin | 59% | 57% | Up 2 percentage points |
| Operating income | $9.8 million | $2.2 million | Up 348% |
| Net income | $7.5 million | $(3.0) million | Returned to profitability |
| Diluted EPS | $1.86 | $(0.79) | Improved |
| Operating cash flow | $30.6 million | $25.7 million | Up 19% |
| Cash and equivalents | $10.2 million | $5.5 million | Up $4.7 million |
| Working capital | $10.0 million | $14.7 million | Down $4.7 million |
Product revenue increased to $81.8 million from $74.4 million, while service revenue declined to $21.3 million from $21.8 million. Adjusted operating income, a non-GAAP measure excluding amortization, stock-based compensation, and impairment charges, was $25.9 million versus $24.6 million.
Interest-bearing debt declined to $23.0 million from $46.6 million. The company had $74.0 million of unused credit capacity, subject to covenants, and was in compliance with its debt agreements. Debt is variable-rate; management estimated that a one-percentage-point increase in interest rates would increase annual interest expense by approximately $356,000.
Investing cash outflow was $3.9 million, including $4.8 million for acquisitions and $1.3 million for capital expenditures. Financing cash outflow was $21.7 million, primarily reflecting debt repayments, dividends, and contingent consideration payments. The quarterly dividend remained $0.16 per share, or $0.64 per share for the year.
Material Changes Versus the Prior Comparable Period
- Organic revenue growth was approximately 3%; reported growth also benefited from acquisitions.
- Sterilization and Disinfection Control revenue increased 7%, primarily from the 2018 BAG and SIMICON acquisitions.
- Instruments revenue increased 6%, supported by order timing and modest pricing actions.
- Cold Chain Monitoring revenue increased 6%, including the Point Six Wireless acquisition completed during fiscal 2019.
- Cold Chain Packaging revenue increased 18% because the largest customer’s order rate normalized; however, that customer subsequently gave 90 days’ notice of contract termination.
- General and administrative expense increased $5.0 million, driven mainly by higher salaries, incentive compensation, and stock-based compensation. A change in forfeiture methodology produced a one-time $945,000 increase in stock-based compensation expense.
- The company recorded $4.8 million of impairment charges in fiscal 2019, compared with $13.8 million in fiscal 2018, primarily related to Cold Chain Packaging.
- A $3.3 million legal settlement expense was recorded in fiscal 2019.
- The company completed the relocation of its Traverse City and former Bozeman operations and sold the old Bozeman facility, recognizing a $288,000 gain.
Guidance, Outlook, Risks, and Unusual Items
Management expects continued growth in Sterilization and Disinfection Control, Instruments, and Cold Chain Monitoring, supported by regulatory-driven demand, new products, improved commercial channels, and acquisitions. No specific revenue or earnings guidance was provided. Management indicated that the ongoing effective tax rate would generally be approximately 26%, subject to the impact of share-based compensation tax effects.
Mesa decided to exit the Cold Chain Packaging business by or before March 31, 2020. The division had fiscal 2019 revenue of $6.9 million and a gross margin of only 9%. The company expects substantially lower fiscal 2020 revenue, further impairment charges of approximately $313,000 for remaining goodwill and intangible assets, and additional restructuring costs of approximately $150,000 to $220,000.
The company expects $150,000 to $200,000 of cash payments related to consolidating Canadian administrative functions into Lakewood, Colorado. It also expects to pay the $3.3 million legal settlement during fiscal 2020.
Key risks include economic and customer capital-spending volatility, competition and pricing pressure, regulatory and FDA compliance, product defects or recalls, cybersecurity and data privacy incidents, foreign currency exposure, tariffs and international operations, integration and valuation risks from acquisitions, impairment of goodwill and intangible assets, variable-rate debt, supply-chain concentration, litigation, tax uncertainty, and the ability to execute the Cold Chain Packaging exit.
Auditors issued unqualified opinions on the fiscal 2019 financial statements and internal control over financial reporting. Management also concluded that disclosure controls and internal control over financial reporting were effective as of March 31, 2019.
Investor Verification Checklist
- Verify the applicable period: the supplied filing is fiscal year 2019, not 2017 Q4.
- Assess the expected revenue and cash-flow impact of terminating the Cold Chain Packaging business and losing its largest customer.
- Review the $4.8 million fiscal 2019 impairment charge and the potential for additional charges during the exit.
- Confirm debt maturities, variable-rate exposure, covenant compliance, and the reported $74.0 million of unused credit capacity.
- Evaluate the sustainability of earnings excluding the $3.3 million legal settlement, impairment charges, amortization, and stock-based compensation.
- Review acquisition performance, including Point Six Wireless, and subsequent fiscal 2019 acquisitions or post-period transactions, including IBP Medical.
- Assess the effect of the $945,000 stock-based compensation adjustment and continuing equity dilution.
- Monitor restructuring costs, the legal settlement payment, tax exposures, foreign currency movements, and regulatory or cybersecurity developments.